Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023
For the full year, revenue was SEK 0.005 million compared to SEK 0.07 million a year ago. Net loss was SEK 18.35 million compared to SEK 20.15 million a year ago. Basic loss per share from continuing operations was SEK 0.758 compared to SEK 1.4 a year ago. Diluted loss per share from continuing operations was SEK 0.758 compared to SEK 1.4 a year ago.